Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses

Cancer Cell

Volumn 25, Issue 1, 2014, Pages 37-48

  Yang, Xuanming ^a,b   Zhang, Xunmin ^a,c   Fu, MayLynne ^b   Weichselbaum, RalphR ^d   Gajewski, ThomasF ^b   Guo, Yajun ^c   Fu, Yang Xin ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHICAGO   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; CETUXIMAB; CYTOKINE; EGFR IFNBETA FUSION PROTEIN; HYBRID PROTEIN; INTERFERON; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETIC TRANSFECTION; INNATE IMMUNITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; ANTIGENS, CD274; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MICROENVIRONMENT;

EID: 84892416698     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.12.004     Document Type: Article

References (44)

1. Abès R., Gélizé E., Fridman W.H., Teillaud J.L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010, 116:926-934.
2. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J.Clin. Oncol. 2010, 28:1254-1261.
3. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by Tcell receptor (TCR) transgenic CD8+ Tcells. Cancer Res. 2004, 64:1140-1145.
4. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., Fuh G. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
5. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N.Engl. J. Med. 2012, 366:2455-2465.
6. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
7. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fcreceptors modulate invivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
8. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J.Clin. Oncol. 1999, 17:2639-2648.
9. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J.Exp. Med. 2011, 208:1989-2003.
10. Fayad L., Offner F., Smith M.R., Verhoef G., Johnson P., Kaufman J.L., Rohatiner A., Advani A., Foran J., Hess G., et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J.Clin. Oncol. 2013, 31:573-583.
11. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ Tcell responses through CD8alpha+ dendritic cells. J.Exp. Med. 2011, 208:2005-2016.
12. González-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
13. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264:961-965.
14. Hurvitz S.A., Dirix L., Kocsis J., Bianchi G.V., Lu J., Vinholes J., Guardino E., Song C., Tong B., Ng V., et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J.Clin. Oncol. 2013, 31:1157-1163.
15. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
16. Kamphuis E., Junt T., Waibler Z., Forster R., Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108:3253-3261.
17. + Tcells in the lung airways during respiratory virus challenge. Immunity 2010, 33:96-105.
18. Krop I.E., LoRusso P., Miller K.D., Modi S., Yardley D., Rodriguez G., Guardino E., Lu M., Zheng M., Girish S., et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J.Clin. Oncol. 2012, 30:3234-3241.
19. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat. Rev. Immunol. 2010, 10:403-414.
20. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., Beckett M., Sharma R., Chin R., Tu T., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ Tcells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
21. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
22. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
23. + Tcells. Clin. Cancer Res. 2013, 19:1476-1486.
24. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J.Clin. Oncol. 2008, 26:1789-1796.
25. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., Sattar H., Wang Y., Brown N.K., Greene M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
26. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006, 20:1496-1510.
27. Rovero S., Amici A., Di Carlo E., Bei R., Nanni P., Quaglino E., Porcedda P., Boggio K., Smorlesi A., Lollini P.L., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J.Immunol. 2000, 165:5133-5142.
28. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
29. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
30. Smith K., Garman L., Wrammert J., Zheng N.Y., Capra J.D., Ahmed R., Wilson P.C. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 2009, 4:372-384.
31. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., Teng M.W., Smyth M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 2011, 108:7142-7147.
32. Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 2012, 30:1-22.
33. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., Schreiber R.D., de la Torre J.C., Oldstone M.B. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
34. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N.Engl. J. Med. 2012, 366:2443-2454.
35. Trinchieri G. Type I interferon: friend or foe?. J.Exp. Med. 2010, 207:2053-2063.
36. Wall E.M., Milne K., Martin M.L., Watson P.H., Theiss P., Nelson B.H. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred Tcells. Cancer Res. 2007, 67:6442-6450.
37. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies ofclinical response and immune-related adverse events. Oncologist 2007, 12:864-872.
38. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., Gondi V., Hsu K.T., Harari P.M. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
39. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., Aronow B.J., Karp C.L., Brooks D.G. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
40. Xuan C., Steward K.K., Timmerman J.M., Morrison S.L. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010, 115:2864-2871.
41. Yang T., Martin M.L., Nielsen J.S., Milne K., Wall E.M., Lin W., Watson P.H., Nelson B.H. Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ Tcells lacking the Cbl-b gene. Cancer Immunol. Immunother. 2009, 58:1865-1875.
42. Yang X., Zhang X., Mortenson E.D., Radkevich-Brown O., Wang Y., Fu Y.X. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol. Ther. 2013, 21:91-100.
43. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011, 3:99ra86.
44. Yoon J., Koo K.H., Choi K.Y. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011, 71:445-453.